| Business Summary | | Curis,
Inc.
is
developing
products
based
on
technologies
in
the
emerging
field
of
regenerative
medicine.
The
Company
is
combining
insights
gained
through
the
study
of
developmental
biology
with
high-throughput
screening
capabilities,
proteins,
cells
and
biocompatible
materials
to
facilitate
the
development
of
new
regenerative
medicine
therapies.
Curis'
product
pipeline
will
include:
a
product
which
is
currently
under
regulatory
review
in
the
United
States,
Europe
and
Australia;
products
in
late-stage
clinical
development;
numerous
early
clinical
and
advanced
preclinical
products;
and
a
discovery
engine
that
combines
functional
genomics
and
developmental
biology
across
multiple
medical
indications.
The
Company
was
formed
in
August
2000
following
the
merger
between
Creative
Biomolecules,
Inc.,
Ontogeny,
Inc.,
and
Reprogenesis,
Inc. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Curis,
Inc.
is
developing
products
based
on
technologies
in
the
emerging
field
of
regenerative
medicine.
For
the
three
months
ended
3/31/01,
revenues
fell
63%
to
$249
thousand.
Net
loss
totaled
$17.8
million,
up
from
$5.8
million.
Revenues
reflect
the
absence
of
contract
revenue
from
Stryker
recognized
in
2000.
Loss
also
reflects
costs
associated
with
the
consolidation
of
three
companies
and
increased
amortization
and
stock-based
compensation
costs. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
203;
after
tax
earnings
were
-19,277. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| Doros Platika, M.D., 47 Pres,
CEO, Director | $634K | -- | Andrew Uprichard, M.D. COO | -- | -- | George Eldridge, 37 VP,
CFO, Treasurer | 135K | $27K | Bruce Leicher, 44 VP,
Gen. Counsel, Sec. | -- | -- | Lynn Baird, Ph.D., 52 VP
of Regulatory Affairs, QA/QC and Preclinical Devel. | 171K | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|